Listen: Is 23andMe Trading Your DNA? With Maria Liu from First Health Advisory Solutions

 

23andMe, the genetic testing company, just announced that it will be entering a 4-year partnership with pharmaceutical giant GlaxoSmithKline (GSK) to develop new drugs and therapies.

As part of the partnership, 23andMe will share voluntarily-shared genetic data with the big pharma company. Maria Liu from First Health Advisory Solutions joined us to talk about the security concerns and potential worries that come with companies sharing medical data.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @HealthMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

patient
Rebecca Interview: When Peer-to-Peer Reviews Stop Being About the Patient
December 2, 2025

Behind the sterile labels of “inpatient” versus “observation” care is a messy reality: clinicians and insurers often enter peer-to-peer reviews without a shared rulebook, turning what should be a clinical dialogue into a box-checking exercise. The speaker’s frustration points to a broader problem in U.S. healthcare utilization management—decisions about coverage can feel pre-decided,…

Read More
physician advisor
Navigating Payer Denials: A Physician Advisor’s Perspective #2
December 2, 2025

A physician advisor recently described a case that should unsettle anyone who cares about fair, clinically grounded coverage decisions: a Medicaid patient arrived comatose from an overdose, was emergently intubated, developed aspiration pneumonia, and stayed through three midnights before leaving against medical advice. By any bedside standard, this is acute, unstable care—exactly what…

Read More
Inside ERISA Denials: Why Employers May Be the Real Decision-Makers Behind Your Insurance Card
December 2, 2025

Insurance denials aren’t new, but they’re hitting a breaking point right now. As prior authorizations surge and patients face longer delays for everything from imaging to specialty drugs, more providers are realizing that the “payer” on the card often isn’t the one truly holding the reins. A growing share of Americans are covered…

Read More
Laying Out the Landscape in Today’s Patient Monitoring
Laying Out the Landscape in Today’s Patient Monitoring
December 2, 2025

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow. This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring. Intel’s Kaeli Tully, Solutions Engineer…

Read More